Hematology. Individualized methotrexate dosing in primary CNS lymphoma.
Although high-dose methotrexate is widely accepted as the most effective chemotherapeutic agent for primary cns lymphoma, no optimal dose or dosing strategy has been established. Researchers from the International Extranodal Lymphoma Study Group used clinical trial data to explore whether or not an area under the curve model might be useful to optimize methotrexate dosing. The results strongly suggest that effective methotrexate dose is an important variable in patient outcome.
Abrey
Lauren E
LE
Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. abreyl@mskcc.org
D000970:Antineoplastic Agents / Q000627:therapeutic use; D016543:Central Nervous System Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006403:Hematologic Tests; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008727:Methotrexate / Q000008:administration & dosage* / Q000627:therapeutic use*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D008727:Methotrexate